Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2026

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Esophageal CancerAdvanced Solid Tumor

Interventions

DRUG

Larotinib

Capsules, Oral, 350 mg, single dose, one day

Trial Locations (1)

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY